SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of...

Descripción completa

Detalles Bibliográficos
Autores principales: Avery, Robert L., Castellarin, Alessandro A., Steinle, Nathan C., Dhoot, Dilsher S., Pieramici, Dante J., See, Robert, Couvillion, Stephen, Nasir, Ma'an A., Rabena, Melvin D., Maia, Mauricio, Van Everen, Sherri, Le, Kha, Hanley, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2017
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642319/
https://www.ncbi.nlm.nih.gov/pubmed/28106709
http://dx.doi.org/10.1097/IAE.0000000000001493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642319/
https://www.ncbi.nlm.nih.gov/pubmed/28106709
http://dx.doi.org/10.1097/IAE.0000000000001493

Ejemplares similares